Table 2 Univaraite and multivariate analysis of DFS in cervical cancer patients
From: Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
DFS (univariate analysis) | DFS (multivariate analysis) | |||||
|---|---|---|---|---|---|---|
HR | 95%CI | p | HR | 95%CI | p | |
Age (< 40/≥40) | 1.158 | 0.473–2.834 | 0.748 | |||
Histo-grade (I-II/III) | 1.146 | 0.468–2.804 | 0.765 | |||
Figo stage (Ib2/ IIa2) | 2.456 | 1.199–5.033 | 0.014 | 2.386 | 1.119–5.089 | 0.024 |
Clinical response (CR/non-CR) | 0.441 | 0.214–0.909 | 0.026 | 0.531 | 0.239–1.180 | 1.120 |
Lymph-node metastasis (yes/no) | 2.702 | 1.104–6.616 | 0.030 | 1.251 | 0.448–3.497 | 0.669 |
PDL1 after NAC (High/Low) | 0.893 | 0.624–1.279 | 0.537 | |||
PDL1 (increase or stable/decrease) | 0.299 | 0.091–0.987 | 0.048 | 0.370 | 0.108–1.266 | 0.113 |
CD3 after NAC (High/Low) | 0.744 | 0.361–1.532 | 0.423 | |||
CD4 after NAC (High/Low) | 0.856 | 0.418–1.755 | 0.672 | |||
CD8 after NAC (High/Low) | 0.471 | 0.221–1.007 | 0.052 | 0.493 | 0.228–1.065 | 0.072 |